SELLEST OSAST
In this episode with Dr Robert Puckrin, we discuss the unmet needs of double-exposed patients with CLL/SLL, as well as the current and novel treatments that can address this gap.
Our guest
Dr. Puckrin is a Hematologist and Clinician Investigator at the Arthur Child Comprehensive Cancer Centre and Alberta Blood and Marrow Transplant Program. He is also a clinical assistant professor at the University of Calgary. Dr Puckrin has received honoraria for advisory boards and/or speaking engagements from Abbvie, Astrazeneca, BeOne, Eli Lilly, Incyte, Kite, Janssen,Pfizer, Roche, and Seagen.
Please provide your feedback on this episode by filling out this quick survey at the following link: https://survey.decipherinc.com/survey/selfserve/53b/g00e/2511135
Funding for this episode was provided by Eli Lilly Canada.
This information is intended solely for educational purposes and is not intended to promote the use of any Eli Lilly Canada medication. All materials or information provided by Eli Lilly Canada Inc. for this learning program comply with applicable regulatory standards.
Editorial control of this learning program resides with the speaker within the parameters of the Innovative Medicines Canada Code and Eli Lilly Policy.
Eli Lilly Canada supports discussion of its products consistent with the approved prescribing information in the product monograph.
Any off-label discussion of products represents the personal opinion of the speaker.
